The Tools for Virulence of Cryptococcus neoformans

Advances in Applied Microbiology

Volumn 87, Issue , 2014, Pages 1-41

  Coelho, Carolina ^a,b   Bocca, Anamelia Lorenzetti ^c   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Amoeba macrophage; Antimicrobial mechanisms; Capsule; Evolution; Fungal immunity; Pbl1; Trojan horse; Virulence factors

Indexed keywords

DEAD BOX PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LACCASE; MELANIN; PHOSPHOLIPASE; UREASE; VIRULENCE FACTOR;

ANTIGEN RECOGNITION; ARTICLE; AUTOPHAGY; BLOOD BRAIN BARRIER; BRAIN INFECTION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; EXOCYTOSIS; FUNGAL CAPSULE; FUNGAL METABOLISM; FUNGAL STRUCTURES; FUNGAL VIRULENCE; FUNGUS GROWTH; HEAT TOLERANCE; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; NONHUMAN; OXIDATIVE STRESS; PH; PHAGOCYTOSIS; PHAGOSOME; SIGNAL TRANSDUCTION; STARVATION; SURVIVAL; T LYMPHOCYTE;

AMOEBA-MACROPHAGE; ANTIMICROBIAL MECHANISMS; CAPSULE; EVOLUTION; FUNGAL IMMUNITY; PBL1; TROJAN HORSE; VIRULENCE FACTORS;

ANIMALS; BLOOD-BRAIN BARRIER; CRYPTOCOCCUS NEOFORMANS; EXOCYTOSIS; HUMANS; VIRULENCE;

EID: 84894505719     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800261-2.00001-3     Document Type: Chapter

References (239)

1. Alanio A., Desnos-Ollivier M., Dromer F. Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. MBio 2011, 00158-11.
2. Alspaugh J.A., Granger D.L. Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infection and Immunity 1991, 59:2291-2296.
3. Alvarez M., Burn T., Luo Y., Pirofski L.A., Casadevall A. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiology 2009, 9:51.
4. Alvarez M., Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Current Biology 2006, 16:2161-2165.
5. Apidianakis Y., Rahme L.G., Heitman J., Ausubel F.M., Calderwood S.B., Mylonakis E. Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryotic Cell 2004, 3:413-419.
6. Appelberg R. Macrophage nutriprive antimicrobial mechanisms. Journal of Leukocyte Biology 2006, 79:1117-1128.
7. Araujo Gde S., Fonseca F.L., Pontes B., Torres A., Cordero R.J., Zancope-Oliveira R.M., et al. Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells. PloS One 2012, 7:e29561.
8. Artavanis-Tsakonas K., Love J.C., Ploegh H.L., Vyas J.M. Recruitment of CD63 to Cryptococcus neoformans phagosomes requires acidification. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15945-15950.
9. Bailao A.M., Schrank A., Borges C.L., Dutra V., Walquiria Ines Molinari-Madlum E.E., Soares Felipe M.S., et al. Differential gene expression by Paracoccidioides brasiliensis in host interaction conditions: Representational difference analysis identifies candidate genes associated with fungal pathogenesis. Microbes and Infection/Institut Pasteur 2006, 8:2686-2697.
10. Baker R.D., Haugen R.K. Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases. American Journal of Clinical Pathology 1955, 25:14-24.
11. Barnett J.A. A history of research on yeasts 14: Medical yeasts part 2, Cryptococcus neoformans. Yeast 2010, 27:875-904.
12. Ben-Abdallah M., Sturny-Leclere A., Ave P., Louise A., Moyrand F., Weih F., et al. Fungal-induced cell cycle impairment, chromosome instability and apoptosis via differential activation of NF-kappaB. PLoS Pathogens 2012, 8:e1002555.
13. Bouklas T., Pechuan X., Goldman D.L., Edelman B., Bergman A., Fries B.C. Old Cryptococcus neoformans cells contribute to virulence in chronic cryptococcosis. mBio 2013, 4:e00455-13.
14. Brown J.C.S., Madhani H.D. Approaching the functional annotation of fungal virulence factors using cross-species genetic interaction profiling. PLoS Genetics 2012, 8:e1003168.
15. Bunting L.A., Neilson J.B., Bulmer G.S. Cryptococcus neoformans: Gastronomic delight of a soil ameba. Sabouraudia 1979, 17:225-232.
16. Cadieux B., Lian T., Hu G., Wang J., Biondo C., Teti G., et al. The Mannoprotein Cig1 supports iron acquisition from heme and virulence in the pathogenic fungus Cryptococcus neoformans. The Journal of Infectious Diseases 2013, 207:1339-1347.
17. Carnell M., Zech T., Calaminus S.D., Ura S., Hagedorn M., Johnston S.A., et al. Actin polymerization driven by WASH causes V-ATPase retrieval and vesicle neutralization before exocytosis. The Journal of Cell Biology 2011, 193:831-839.
18. Casadevall A. Cryptococci at the brain gate: Break and enter or use a Trojan horse?. The Journal of Clinical Investigation 2010, 120:1389-1392.
19. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Goldman D.L., Kozel T.R., et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrobial Agents and Chemotherapy 1998, 42:1437-1446.
20. Casadevall A., Pirofski L.A. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity. Infection and Immunity 1999, 67:3703-3713.
21. Casadevall A., Pirofski L.A. Microbial virulence results from the interaction between host and microorganism. Trends in Microbiology 2003, 11:157-158. author reply 158-159.
22. Casadevall A., Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Current Molecular Medicine 2005, 5:421-433.
23. Chang Y.C., Kwon-Chung K.J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Molecular and Cellular Biology 1994, 14:4912-4919.
24. Chang Y.C., Kwon-Chung K.J. Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infection and Immunity 1998, 66:2230-2236.
25. Chang Y.C., Kwon-Chung K.J. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. Journal of Bacteriology 1999, 181:5636-5643.
26. Chang Z.L., Netski D., Thorkildson P., Kozel T.R. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages. Infection and Immunity 2006, 74:144-151.
27. Chang Y.C., Stins M.F., McCaffery M.J., Miller G.F., Pare D.R., Dam T., et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infection and Immunity 2004, 72:4985-4995.
28. Charlier C., Chretien F., Baudrimont M., Mordelet E., Lortholary O., Dromer F. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. The American Journal of Pathology 2005, 166:421-432.
29. Charlier C., Nielsen K., Daou S., Brigitte M., Chretien F., Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infection and Immunity 2009, 77:120-127.
30. Chaturvedi V., Wong B., Newman S.L. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. Journal of Immunology 1996, 156:3836-3840.
31. Chayakulkeeree M., Johnston S.A., Oei J.B., Lev S., Williamson P.R., Wilson C.F., et al. SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Molecular Microbiology 2011, 80:1088-1101.
32. Chen S., Sun B. Negative regulation of NLRP3 inflammasome signaling. Protein & Cell 2013, 4:251-258.
33. Chiapello L.S., Baronetti J.L., Garro A.P., Spesso M.F., Masih D.T. Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway. International Immunology 2008, 20:1527-1541.
34. Choi J.N., Kim J., Kim J., Jung W.H., Lee C.H. Influence of iron regulation on the metabolome of Cryptococcus neoformans. PloS One 2012, 7:e41654.
35. Chrisman C.J., Albuquerque P., Guimaraes A.J., Nieves E., Casadevall A. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathogens 2011, 7:e1002047.
36. Chun C.D., Liu O.W., Madhani H.D. A link between virulence and homeostatic responses to hypoxia during infection by the human fungal pathogen Cryptococcus neoformans. PLoS pathogens 2007, 3. e22.17319742.
37. Chun C.D., Brown J.C., Madhani H.D. A major role for capsule-independent phagocytosis-inhibitory mechanisms in mammalian infection by Cryptococcus neoformans. Cell Host & Microbe 2011, 9:243-251.
38. Cordero R.J., Frases S., Guimaraes A.J., Rivera J., Casadevall A. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Molecular Microbiology 2011, 79:1101-1117.
39. Cordero R.J., Pontes B., Frases S., Nakouzi A.S., Nimrichter L., Rodrigues M.L., et al. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. Journal of Immunology 2013, 190:317-323.
40. Cordero R.J., Pontes B., Guimaraes A.J., Martinez L.R., Rivera J., Fries B.C., et al. Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans. Infection and Immunity 2011, 79:4990-5000.
41. Cox G.M., Harrison T.S., McDade H.C., Taborda C.P., Heinrich G., Casadevall A., et al. Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infection and Immunity 2003, 71:173-180.
42. Cox G.M., McDade H.C., Chen S.C., Tucker S.C., Gottfredsson M., Wright L.C., et al. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Molecular Microbiology 2001, 39:166-175.
43. Cox G.M., Mukherjee J., Cole G.T., Casadevall A., Perfect J.R. Urease as a virulence factor in experimental cryptococcosis. Infection and Immunity 2000, 68:443-448.
44. Crabtree J.N., Okagaki L.H., Wiesner D.L., Strain A.K., Nielsen J.N., Nielsen K. Titan cell production enhances the virulence of Cryptococcus neoformans. Infection and Immunity 2012, 80:3776-3785.
45. Cross C.E., Bancroft G.J. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infection and Immunity 1995, 63:2604-2611.
46. Dadachova E., Bryan R.A., Howell R.C., Schweitzer A.D., Aisen P., Nosanchuk J.D., et al. The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell & Melanoma Research 2008, 21:192-199.
47. Davis J., Zheng W.Y., Glatman-Freedman A., Ng J.A., Pagcatipunan M.R., Lessin H., et al. Serologic evidence for regional differences in pediatric cryptococcal infection. The Pediatric Infectious Disease Journal 2007, 26:549-551.
48. de Jesus-Berrios M., Liu L., Nussbaum J.C., Cox G.M., Stamler J.S., Heitman J. Enzymes that counteract nitrosative stress promote fungal virulence. Current Biology 2003, 13:1963-1968.
49. Del Poeta M. Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryotic Cell 2004, 3:1067-1075.
50. Del Poeta M., Casadevall A. Ten challenges on Cryptococcus and cryptococcosis. Mycopathologia 2012, 173:303-310.
51. Derengowski Lda S., Paes H.C., Albuquerque P., Tavares A.H., Fernandes L., Silva-Pereira I., et al. The transcriptional response of Cryptococcus neoformans to ingestion by Acanthamoeba castellanii and macrophages provides insights into the evolutionary adaptation to the mammalian host. Eukaryotic Cell 2013, 12:761-774.
52. Diamond R.D., May J.E., Kane M.A., Frank M.M., Bennett J.E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. Journal of Immunology 1974, 112:2260-2270.
53. Ding C., Festa R.A., Chen Y.L., Espart A., Palacios O., Espin J., et al. Cryptococcus neoformans copper detoxification machinery is critical for fungal virulence. Cell Host & Microbe 2013, 13:265-276.
54. Dromer F., Ronin O., Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: Evidence for dormant infection in healthy subjects. Journal of Medical and Veterinary Mycology 1992, 30:395-397.
55. Doering T.L., Nosanchuk J.D., Roberts W.K., Casadevall A. Melanin as a potential cryptococcal defence against microbicidal proteins. Medical Mycology: Official Publication of the International Society for Human and Animal Mycology 1999, 37:175-181.
56. Ellerbroek P.M., Ulfman L.H., Hoepelman A.I., Coenjaerts F.E. Cryptococcal glucuronoxylomannan interferes with neutrophil rolling on the endothelium. Cellular Microbiology 2004, 6:581-592.
57. Ellerbroek P.M., Walenkamp A.M., Hoepelman A.I., Coenjaerts F.E. Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators. Current Medicinal Chemistry 2004, 11:253-266.
58. Erb-Downward J.R., Huffnagle G.B. Cryptococcus neoformans produces authentic prostaglandin E2 without a cyclooxygenase. Eukaryotic Cell 2007, 6:346-350.
59. Fan W., Kraus P.R., Boily M.J., Heitman J. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryotic Cell 2005, 4:1420-1433.
60. Feldmesser M., Casadevall A. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. Journal of Immunology 1997, 158:790-799.
61. Feldmesser M., Kress Y., Novikoff P., Casadevall A. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infection and Immunity 2000, 68:4225-4237.
62. Feldmesser M., Rivera J., Kress Y., Kozel T.R., Casadevall A. Antibody interactions with the capsule of Cryptococcus neoformans. Infection and Immunity 2000, 68:3642-3650.
63. Fernandez-Arenas E., Cabezon V., Bermejo C., Arroyo J., Nombela C., Diez-Orejas R., et al. Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction. Molecular & Cellular Proteomics 2007, 6:460-478.
64. Fonseca F.L., Nimrichter L., Cordero R.J.B., Frases S., Rodrigues J., Goldman D.L., et al. Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans. Eukaryotic Cell 2009, 8:1543-1553.
65. Fonseca F.L., Nohara L.L., Cordero R.J., Frases S., Casadevall A., Almeida I.C., et al. Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter. Infection and Immunity 2010, 78:3861-3870.
66. Frager S.Z., Chrisman C.J., Shakked R., Casadevall A. Paramecium species ingest and kill the cells of the human pathogenic fungus Cryptococcus neoformans. Medical Mycology 2010, 48:775-779.
67. Fries B.C., Lee S.C., Kennan R., Zhao W., Casadevall A., Goldman D.L. Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. Infection and Immunity 2005, 73:1779-1787.
68. Fries B.C., Taborda C.P., Serfass E., Casadevall A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. The Journal of Clinical Investigation 2001, 108:1639-1648.
69. Garcia-Hermoso D., Janbon G., Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. Journal of Clinical Microbiology 1999, 37:3204-3209.
70. Garcia-Rivera J., Chang Y.C., Kwon-Chung K.J., Casadevall A. Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryotic Cell 2004, 3:385-392.
71. Garcia-Solache M.A., Izquierdo-Garcia D., Smith C., Bergman A., Casadevall A. Fungal virulence in a lepidopteran model is an emergent property with deterministic features. mBio 2013, 4:e00100-e00113.
72. Giles S.S., Batinic-Haberle I., Perfect J.R., Cox G.M. Cryptococcus neoformans mitochondrial superoxide dismutase: An essential link between antioxidant function and high-temperature growth. Eukaryotic Cell 2005, 4:46-54.
73. Giles S.S., Dagenais T.R., Botts M.R., Keller N.P., Hull C.M. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infection and Immunity 2009, 77:3491-3500.
74. Goldman D., Cho Y., Zhao M., Casadevall A., Lee S.C. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. The American Journal of Pathology 1996, 148:1275-1282.
75. Goldman D.L., Fries B.C., Franzot S.P., Montella L., Casadevall A. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14967-14972.
76. Goldman D.L., Khine H., Abadi J., Lindenberg D.J., Pirofski L., Niang R., et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001, 107:E66.
77. Goldman D., Lee S.C., Casadevall A. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infection and Immunity 1994, 62:4755-4761.
78. Goldman D.L., Lee S.C., Mednick A.J., Montella L., Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infection and Immunity 2000, 68:832-838.
79. Goulart L., Rosae Silva L.K., Chiapello L., Silveira C., Crestani J., Masih D., et al. Cryptococcus neoformans and Cryptococcus gattii genes preferentially expressed during rat macrophage infection. Medical Mycology 2010, 48:932-941.
80. Griffiths E.J., Kretschmer M., Kronstad J.W. Aimless mutants of Cryptococcus neoformans: Failure to disseminate. Fungal Biology Reviews 2012, 26:61-72.
81. Grijpstra J., Gerwig G.J., Wosten H., Kamerling J.P., de Cock H. Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans. Eukaryotic Cell 2009, 8:1165-1173.
82. Grijpstra J., Tefsen B., van Die I., de Cock H. The Cryptococcus neoformans cap10 and cap59 mutant strains, affected in glucuronoxylomannan synthesis, differentially activate human dendritic cells. FEMS Immunology and Medical Microbiology 2009, 57:142-150.
83. Guerrero A., Jain N., Goldman D.L., Fries B.C. Phenotypic switching in Cryptococcus neoformans. Microbiology 2006, 152:3-9.
84. Hajjeh R.A., Conn L.A., Stephens D.S., Baughman W., Hamill R., Graviss E., et al. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. The Journal of Infectious Diseases 1999, 179:449-454.
85. He X., Lyons D.M., Toffaletti D.L., Wang F., Qiu Y., Davis M.J., et al. Virulence factors identified by Cryptococcus neoformans mutant screen differentially modulate lung immune responses and brain dissemination. The American Journal of Pathology 2012, 181:1356-1366.
86. Hoang L.M., Maguire J.A., Doyle P., Fyfe M., Roscoe D.L. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): Epidemiology, microbiology and histopathology. Journal of Medical Microbiology 2004, 53:935-940.
87. Hole C.R., Bui H., Wormley F.L., Wozniak K.L. Mechanisms of dendritic cell lysosomal killing of Cryptococcus. Scientific Reports 2012, 2:739.
88. Hu G., Cheng P.Y., Sham A., Perfect J.R., Kronstad J.W. Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Molecular Microbiology 2008, 69:1456-1475.
89. Hu G., Hacham M., Waterman S.R., Panepinto J., Shin S., Liu X., et al. PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans. The Journal of Clinical Investigation 2008, 118:1186-1197.
90. Hu G., Steen B.R., Lian T., Sham A.P., Tam N., Tangen K.L., et al. Transcriptional regulation by protein kinase A in Cryptococcus neoformans. PLoS Pathogens 2007, 3:e42.
91. Huang S.H., Wu C.H., Chang Y.C., Kwon-Chung K.J., Brown R.J., Jong A. Cryptococcus neoformans-derived microvesicles enhance the pathogenesis of fungal brain infection. PloS One 2012, 7:e48570.
92. Huffnagle G.B., Chen G.H., Curtis J.L., McDonald R.A., Strieter R.M., Toews G.B. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. Journal of Immunology 1995, 155:3507-3516.
93. Ikeda R., Sugita T., Jacobson E.S., Shinoda T. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiology and Immunology 2003, 47:271-277.
94. Jain N., Guerrero A., Fries B.C. Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Research 2006, 6:480-488.
95. Jain N., Li L., McFadden D.C., Banarjee U., Wang X., Cook E., et al. Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infection and Immunity 2006, 74:896-903.
96. Jarvis J.N., Casazza J.P., Stone H.H., Meintjes G., Lawn S.D., Levitz S.M., et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. The Journal of Infectious Diseases 2013, 207:1817-1828.
97. Jarvis J.N., Harrison T.S. HIV-associated cryptococcal meningitis. AIDS 2007, 21:2119-2129.
98. Jesus M.D., Nicola A.M., Chow S.K., Lee I.R., Nong S., Specht C.A., et al. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence 2010, 1:500-508.
99. Johnston S.A., May R.C. The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. PLoS Pathogens 2010, 6:e1001041.
100. Jung W.H., Hu G., Kuo W., Kronstad J.W. Role of ferroxidases in iron uptake and virulence of Cryptococcus neoformans. Eukaryotic Cell 2009, 8:1511-1520.
101. Jung W.H., Kronstad J.W. Iron and fungal pathogenesis: A case study with Cryptococcus neoformans. Cellular Microbiology 2008, 10:277-284.
102. Kawakami K., Koguchi Y., Qureshi M.H., Zhang T., Kinjo Y., Yara S., et al. Anti-CD11 b monoclonal antibody suppresses brain dissemination of Cryptococcus neoformans in mice. Microbiology and Immunology 2002, 46:181-186.
103. Kechichian T.B., Shea J., Del Poeta M. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infection and Immunity 2007, 75:4792-4798.
104. Kim J., Cho Y.-J., Do E., Choi J., Hu G., Cadieux B., et al. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs. Fungal Genetics and Biology 2012, 49:955-966.
105. Kim W.K., Corey S., Alvarez X., Williams K. Monocyte/macrophage traffic in HIV and SIV encephalitis. Journal of Leukocyte Biology 2003, 74:650-656.
106. Kim J.-C., Crary B., Chang Y.C., Kwon-Chung K.J., Kim K.J. Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier. Journal of Biological Chemistry 2012, 287:36147-36157.
107. Kmetzsch L., Joffe L.S., Staats C.C., de Oliveira D.L., Fonseca F.L., Cordero R.J., et al. Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence. Molecular Microbiology 2011, 81:206-218.
108. Konieczna I., Zarnowiec P., Kwinkowski M., Kolesinska B., Fraczyk J., Kaminski Z., et al. Bacterial urease and its role in long-lasting human diseases. Current Protein & Peptide Science 2012, 13:789-806.
109. Kozel T.R. Opsonization and phagocytosis of Cryptococcus neoformans. Archives of Medical Research 1993, 24:211-218.
110. Kozel T.R., Wilson M.A., Murphy J.W. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infection and Immunity 1991, 59:3101-3110.
111. Kozubowski L., Lee S.C., Heitman J. Signalling pathways in the pathogenesis of Cryptococcus. Cellular Microbiology 2009, 11:370-380.
112. Kronstad J.W., Hu G., Jung W.H. An encapsulation of iron homeostasis and virulence in Cryptococcus neoformans. Trends in Microbiology 2013, 21:457-465.
113. Kuwahara H., Miyamoto Y., Akaike T., Kubota T., Sawa T., Okamoto S., et al. Helicobacter pylori urease suppresses bactericidal activity of peroxynitrite via carbon dioxide production. Infection and Immunity 2000, 68:4378-4383.
114. Kwon-Chung K.J., Polacheck I., Popkin T.J. Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. Journal of Bacteriology 1982, 150:1414-1421.
115. Lamkanfi M. Emerging inflammasome effector mechanisms. Nature Reviews. Immunology 2011, 11:213-220.
116. Lee S.C., Casadevall A. Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1996, 23:194-195.
117. Lee S.C., Casadevall A., Dickson D.W. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. The American Journal of Pathology 1996, 148:1267-1274.
118. Lee S.C., Dickson D.W., Brosnan C.F., Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. The Journal of Experimental Medicine 1994, 180:365-369.
119. Lee S.C., Kress Y., Dickson D.W., Casadevall A. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. Journal of Neuroimmunology 1995, 62:43-52.
120. Lee S.C., Kress Y., Zhao M.L., Dickson D.W., Casadevall A. Cryptococcus neoformans survive and replicate in human microglia. Laboratory Investigation: A Journal of Technical Methods and Pathology 1995, 73:871-879.
121. Lei G., Chen M., Li H., Niu J.L., Wu S., Mao L., et al. Biofilm from a clinical strain of Cryptococcus neoformans activates the NLRP3 inflammasome. Cell Research 2013, 23:965-968.
122. Lev S., Desmarini D., Li C., Chayakulkeeree M., Traven A., Sorrell T.C., et al. Phospholipase C of Cryptococcus neoformans regulates homeostasis and virulence by providing inositol trisphosphate as a substrate for Arg1 kinase. Infection and Immunity 2013, 81:1245-1255.
123. Levitz S.M., Harrison T.S., Tabuni A., Liu X. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. The Journal of Clinical Investigation 1997, 100:1640-1646.
124. Lin X., Heitman J. The biology of the Cryptococcus neoformans species complex. Annual Review of Microbiology 2006, 60:69-105.
125. Lindell D.M., Ballinger M.N., McDonald R.A., Toews G.B., Huffnagle G.B. Immunologic homeostasis during infection: Coexistence of strong pulmonary cell-mediated immunity to secondary Cryptococcus neoformans infection while the primary infection still persists at low levels in the lungs. Journal of Immunology 2006, 177:4652-4661.
126. Lipovsky M.M., Juliana A.E., Gekker G., Hu S., Hoepelman A.I., Peterson P.K. Effect of cytokines on anticryptococcal activity of human microglial cells. Clinical and Diagnostic Laboratory Immunology 1998, 5:410-411.
127. Liu O.W., Chun C.D., Chow E.D., Chen C., Madhani H.D., Noble S.M. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 2008, 135:174-188.
128. Liu G.Y., Nizet V. Color me bad: Microbial pigments as virulence factors. Trends in Microbiology 2009, 17:406-413.
129. Loftus B.J., Fung E., Roncaglia P., Rowley D., Amedeo P., Bruno D., et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 2005, 307:1321-1324.
130. Longo D., Fauci A., Kasper D., Hauser S., Jameson J., Loscalzo J. Harrison principles of internal medicine 2011, McGraw-Hill, New York, NY. 18th ed.
131. Lorenz M.C., Fink G.R. The glyoxylate cycle is required for fungal virulence. Nature 2001, 412:83-86.
132. Luberto C., Martinez-Marino B., Taraskiewicz D., Bolanos B., Chitano P., Toffaletti D.L., et al. Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. The Journal of Clinical Investigation 2003, 112:1080-1094.
133. Lupo P., Chang Y.C., Kelsall B.L., Farber J.M., Pietrella D., Vecchiarelli A., et al. The presence of capsule in Cryptococcus neoformans influences the gene expression profile in dendritic cells during interaction with the fungus. Infection and Immunity 2008, 76:1581-1589.
134. Ma H., Croudace J.E., Lammas D.A., May R.C. Expulsion of live pathogenic yeast by macrophages. Current Biology 2006, 16:2156-2160.
135. Magditch D.A., Liu T.B., Xue C., Idnurm A. DNA mutations mediate microevolution between host-adapted forms of the pathogenic fungus Cryptococcus neoformans. PLoS Pathogens 2012, 8:e1002936.
136. Mansour M.K., Yauch L.E., Rottman J.B., Levitz S.M. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infection and Immunity 2004, 72:1746-1754.
137. Martinez L.R., Garcia-Rivera J., Casadevall A. Cryptococcus neoformans var. neoformans (serotype D) strains are more susceptible to heat than C. neoformans var. grubii (serotype A) strains. Journal of Clinical Microbiology 2001, 39:3365-3367.
138. Maruvada R., Zhu L., Pearce D., Zheng Y., Perfect J., Kwon-Chung K.J., et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cellular Microbiology 2012, 14:1544-1553.
139. Mazzolla R., Barluzzi R., Brozzetti A., Boelaert J.R., Luna T., Saleppico S., et al. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrobial Agents and Chemotherapy 1997, 41:802-807.
140. McClelland E.E., Bernhardt P., Casadevall A. Estimating the relative contributions of virulence factors for pathogenic microbes. Infection and Immunity 2006, 74:1500-1504.
141. McClelland E.E., Hobbs L.M., Rivera J., Casadevall A., Potts W.K., Smith J.M., et al. The role of host gender in the pathogenesis of Cryptococcus neoformans infections. PloS One 2013, 8:e63632.
142. McFadden D.C., Fries B.C., Wang F., Casadevall A. Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryotic Cell 2007, 6:1464-1473.
143. McFadden D., Zaragoza O., Casadevall A. The capsular dynamics of Cryptococcus neoformans. Trends in Microbiology 2006, 14:497-505.
144. Mednick A.J., Nosanchuk J.D., Casadevall A. Melanization of Cryptococcus neoformans affects lung inflammatory responses during cryptococcal infection. Infection and Immunity 2005, 73:2012-2019.
145. Megson G.M., Stevens D.A., Hamilton J.R., Denning D.W. D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. Journal of Clinical Microbiology 1996, 34:218-221.
146. Mershon-Shier K.L., Vasuthasawat A., Takahashi K., Morrison S.L., Beenhouwer D.O. In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways. Molecular Immunology 2011, 48:2009-2018.
147. Missall T.A., Moran J.M., Corbett J.A., Lodge J.K. Distinct stress responses of two functional laccases in Cryptococcus neoformans are revealed in the absence of the thiol-specific antioxidant Tsa1. Eukaryotic Cell 2005, 4:202-208.
148. Missall T.A., Pusateri M.E., Donlin M.J., Chambers K.T., Corbett J.A., Lodge J.K. Posttranslational, translational, and transcriptional responses to nitric oxide stress in Cryptococcus neoformans: Implications for virulence. Eukaryotic Cell 2006, 5:518-529.
149. Missall T.A., Pusateri M.E., Lodge J.K. Thiol peroxidase is critical for virulence and resistance to nitric oxide and peroxide in the fungal pathogen, Cryptococcus neoformans. Molecular Microbiology 2004, 51:1447-1458.
150. Monari C., Pericolini E., Bistoni G., Casadevall A., Kozel T.R., Vecchiarelli A. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. Journal of Immunology 2005, 174:3461-3468.
151. Morrow C.A., Valkov E., Stamp A., Chow E.W.L., Lee I.R., Wronski A., et al. De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans. PLoS Pathogens 2012, 8:e1002957.
152. Müller U., Piehler D., Stenzel W., Köhler G., Frey O., Held J., et al. Lack of IL-4 receptor expression on T helper cells reduces T helper 2 cell polyfunctionality and confers resistance in allergic bronchopulmonary mycosis. Mucosal Immunology 2012, 5:299-310.
153. Murphy J.W., Mosley R.L., Cherniak R., Reyes G.H., Kozel T.R., Reiss E. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infection and Immunity 1988, 56:424-431.
154. Mylonakis E., Ausubel F.M., Perfect J.R., Heitman J., Calderwood S.B. Nonlinear partial differential equations and applications: Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:15675-15680.
155. Mylonakis E., Moreno R., Khoury El J.B., Idnurm A., Heitman J., Calderwood S.B., et al. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infection and Immunity 2005, 73:3842-3850.
156. Nessa K., Gross N.T., Jarstrand C., Johansson A., Camner P. In vivo interaction between alveolar macrophages and Cryptococcus neoformans. Mycopathologia 1997, 139:1-7.
157. Ngamskulrungroj P., Price J., Sorrell T., Perfect J.R., Meyer W. Cryptococcus gattii virulence composite: Candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. PloS One 2011, 6:e16076.
158. Nicola A.M., Robertson E.J., Albuquerque P., Derengowski L.D.S., Casadevall A. Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. MBio 2011, 2. 00167-11.
159. Nimrichter L., Frases S., Cinelli L.P., Viana N.B., Nakouzi A., Travassos L.R., et al. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryotic Cell 2007, 6:1400-1410.
160. Novo E., Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis & Tissue Repair 2008, 1:5.
161. Okagaki L.H., Strain A.K., Nielsen J.N., Charlier C., Baltes N.J., Chretien F., et al. Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathogens 2010, 6:e1000953.
162. Oliveira D.L., Freire-de-Lima C.G., Nosanchuk J.D., Casadevall A., Rodrigues M.L., Nimrichter L. Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infection and Immunity 2010, 78:1601-1609.
163. Oliveira D.L., Nimrichter L., Miranda K., Frases S., Faull K.F., Casadevall A., et al. Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan. Fungal Genetics and Biology 2009, 46:956-963.
164. Olszewski M.A., Noverr M.C., Chen G.H., Toews G.B., Cox G.M., Perfect J.R., et al. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. The American Journal of Pathology 2004, 164:1761-1771.
165. Osterholzer J.J., Surana R., Milam J.E., Montano G.T., Chen G.H., Sonstein J., et al. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. The American Journal of Pathology 2009, 174:932-943.
166. Palmer G.E., Askew D.S., Williamson P.R. The diverse roles of autophagy in medically important fungi. Autophagy 2008, 4:982-988.
167. Panepinto J., Komperda K., Frases S., Park Y.D., Djordjevic J.T., Casadevall A., et al. Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Molecular Microbiology 2009, 71:1165-1176.
168. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
169. Perfect J.R. Cryptococcus neoformans: The yeast that likes it hot. FEMS Yeast Research 2006, 6:463-468.
170. Perfect J.R. The triple threat of cryptococcosis: It's the body site, the strain, and/or the host. mBio 2012, 3:e00165-12.
171. Pericolini E., Alunno A., Gabrielli E., Bartoloni E., Cenci E., Chow S.K., et al. The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. PloS One 2013, 8:e53336.
172. Petter R., Kang B.S., Boekhout T., Davis B.J., Kwon-Chung K.J. A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, CNLAC1 and CAP59. Microbiology 2001, 147:2029-2036.
173. Piccioni M., Monari C., Kenno S., Pericolini E., Gabrielli E., Pietrella D., et al. A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infection and Immunity 2013, 81:90-98.
174. Pietrella D., Cherniak R., Strappini C., Perito S., Mosci P., Bistoni F., et al. Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infection and Immunity 2001, 69:2808-2814.
175. Pietrella D., Fries B., Lupo P., Bistoni F., Casadevall A., Vecchiarelli A. Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response. Cellular Microbiology 2003, 5:513-522.
176. Polacheck I., Hearing V.J., Kwon-Chung K.J. Biochemical studies of phenoloxidase and utilization of catecholamines in Cryptococcus neoformans. Journal of Bacteriology 1982, 150:1212-1220.
177. Pukkila-Worley R., Gerrald Q.D., Kraus P.R., Boily M.J., Davis M.J., Giles S.S., et al. Transcriptional network of multiple capsule and melanin genes governed by the Cryptococcus neoformans cyclic AMP cascade. Eukaryotic Cell 2005, 4:190-201.
178. Qin Q.M., Luo J., Lin X., Pei J., Li L., Ficht T.A., et al. Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. PLoS Pathogens 2011, 7:e1002078.
179. Qiu Y., Davis M.J., Dayrit J.K., Hadd Z., Meister D.L., Osterholzer J.J., et al. Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice. PloS One 2012, 7:e47853.
180. Qiu J., Olszewski M.A., Williamson P.R. Cryptococcus neoformans growth and protection from innate immunity are dependent on expression of a virulence-associated DEAD-box protein, Vad1. Infection and Immunity 2013, 81:777-788.
181. Ramos C.L., Fonseca F.L., Rodrigues J., Guimarães A.J., Cinelli L.P., Miranda K., et al. Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties. Eukaryotic Cell 2012, 11:1086-1094.
182. Rhodes J.C. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 1985, 23:225-234.
183. Rhodes J.C., Polacheck I., Kwon-Chung K.J. Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans. Infection and Immunity 1982, 36:1175-1184.
184. Robert V.A., Casadevall A. Vertebrate endothermy restricts most fungi as potential pathogens. The Journal of Infectious Diseases 2009, 200:1623-1626.
185. Rodrigues M.L., Alvarez M., Fonseca F.L., Casadevall A. Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryotic Cell 2008, 7:602-609.
186. Rodrigues M.L., Nakayasu E.S., Oliveira D.L., Nimrichter L., Nosanchuk J.D., Almeida I.C., et al. Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryotic Cell 2008, 7:58-67.
187. Rodrigues M.L., Nimrichter L., Oliveira D.L., Frases S., Miranda K., Zaragoza O., et al. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryotic Cell 2007, 6:48-59.
188. Rodrigues M.L., Nimrichter L., Oliveira D.L., Nosanchuk J.D., Casadevall A. Vesicular trans-cell wall transport in fungi: A mechanism for the delivery of virulence-associated macromolecules?. Lipid Insights 2008, 2:27-40.
189. Rohatgi S., Gohil S., Kuniholm M.H., Schultz H., Dufaud C., Armour K.L., et al. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. mBio 2013, 4:e00573-13.
190. Rosas A.L., Nosanchuk J.D., Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infection and Immunity 2001, 69:3410-3412.
191. Rude T.H., Toffaletti D.L., Cox G.M., Perfect J.R. Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infection and Immunity 2002, 70:5684-5694.
192. Ruiz A., Neilson J.B., Bulmer G.S. Control of Cryptococcus neoformans in nature by biotic factors. Sabouraudia 1982, 20:21-29.
193. Ruiz A., Neilson J.B., Bulmer G.S. A one year study on the viability of Cryptococcus neoformans in nature. Mycopathologia 1982, 77:117-122.
194. Sabiiti W., May R.C. Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. PloS One 2012, 7:e35455.
195. Salas S.D., Bennett J.E., Kwon-Chung K.J., Perfect J.R., Williamson P.R. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. The Journal of Experimental Medicine 1996, 184:377-386.
196. Salkowski C.A., Balish E. Susceptibility of congenitally immunodeficient mice to a nonencapsulated strain of Cryptococcus neoformans. Canadian Journal of Microbiology 1991, 37:834-839.
197. Schwartz D.A. Characterization of the biological activity of Cryptococcus infections in surgical pathology. The Budding Index and Carminophilic Index. Annals of Clinical and Laboratory Science 1988, 18:388-397.
198. Schwarz P., Dromer F., Lortholary O., Dannaoui E. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrobial Agents and Chemotherapy 2006, 50:113-120.
199. Seider K., Heyken A., Luttich A., Miramon P., Hube B. Interaction of pathogenic yeasts with phagocytes: Survival, persistence and escape. Current Opinion in Microbiology 2010, 13:392-400.
200. Selvan L.D.N., Renuse S., Kaviyil J.E., Sharma J., Pinto S.M., Yelamanchi S.D., et al. Phosphoproteome of Cryptococcus neoformans. Journal of Proteomics 2013, 97:287-295.
201. Shapiro S., Beenhouwer D.O., Feldmesser M., Taborda C., Carroll M.C., Casadevall A., et al. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infection and Immunity 2002, 70:2598-2604.
202. Shea J.M., Kechichian T.B., Luberto C., Del Poeta M. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infection and Immunity 2006, 74:5977-5988.
203. Shi M., Li S.S., Zheng C., Jones G.J., Kim K.S., Zhou H., et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. The Journal of Clinical Investigation 2010, 120:1683-1693.
204. Shoham S., Levitz S.M. The immune response to fungal infections. British Journal of Haematology 2005, 129:569-582.
205. Siegemund S., Alber G. Cryptococcus neoformans activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and down-regulates macrophages. FEMS Immunology and Medical Microbiology 2008, 52:417-427.
206. Singh N., Alexander B.D., Lortholary O., Dromer F., Gupta K.L., John G.T., et al. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2008, 46:e12-e18.
207. Singh A., Panting R.J., Varma A., Saijo T., Waldron K.J., Jong A., et al. Factors required for activation of urease as a virulence determinant in Cryptococcus neoformans. mBio 2013, 4:e00220-13.
208. Stano P., Williams V., Villani M., Cymbalyuk E.S., Qureshi A., Huang Y., et al. App1: An antiphagocytic protein that binds to complement receptors 3 and 2. Journal of Immunology 2009, 182:84-91.
209. Steen B.R., Zuyderduyn S., Toffaletti D.L., Marra M., Jones S.J., Perfect J.R., et al. Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryotic Cell 2003, 2:1336-1349.
210. Steenbergen J.N., Casadevall A. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes and Infection/Institut Pasteur 2003, 5:667-675.
211. Steenbergen J.N., Nosanchuk J.D., Malliaris S.D., Casadevall A. Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infection and Immunity 2003, 71:4862-4872.
212. Steenbergen J.N., Nosanchuk J.D., Malliaris S.D., Casadevall A. Interaction of Blastomyces dermatitidis, Sporothrix schenckii, and Histoplasma capsulatum with Acanthamoeba castellanii. Infection and Immunity 2004, 72:3478-3488.
213. Steenbergen J.N., Shuman H.A., Casadevall A. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:15245-15250.
214. Szymczak W.A., Davis M.J., Lundy S.K., Dufaud C., Olszewski M., Pirofski L.-A. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. mBio 2013, 4:e00265-13.
215. Tabata Y., Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988, 9:356-362.
216. Tangen K.L., Jung W.H., Sham A.P., Lian T., Kronstad J.W. The iron- and cAMP-regulated gene SIT1 influences ferrioxamine B utilization, melanization and cell wall structure in Cryptococcus neoformans. Microbiology 2007, 153:29-41.
217. Tschopp J. Mitochondria: Sovereign of inflammation?. European Journal of Immunology 2011, 41:1196-1202.
218. Tseng H.-K., Liu C.-P., Price M.S., Jong A.Y., Chang J.-C., Toffaletti D.L., et al. Identification of genes from the fungal pathogen Cryptococcus neoformans related to transmigration into the central nervous system. PloS One 2012, 7:e45083.
219. Tucker S.C., Casadevall A. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:3165-3170.
220. Underhill D.M., Goodridge H.S. Information processing during phagocytosis. Nature Reviews. Immunology 2012, 12:492-502.
221. van Duin D., Casadevall A., Nosanchuk J.D. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrobial Agents and Chemotherapy 2002, 46:3394-3400.
222. Varma A., Wu S., Guo N., Liao W., Lu G., Li A., et al. Identification of a novel gene, URE2, that functionally complements a urease-negative clinical strain of Cryptococcus neoformans. Microbiology 2006, 152:3723-3731.
223. Vazquez-Torres A., Stevanin T., Jones-Carson J., Castor M., Read R.C., Fang F.C. Analysis of nitric oxide-dependent antimicrobial actions in macrophages and mice. Methods in Enzymology 2008, 437:521-538.
224. Vecchiarelli A., Pericolini E., Gabrielli E., Chow S.K., Bistoni F., Cenci E., et al. Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy 2011, 3:997-1005.
225. Vecchiarelli A., Pericolini E., Gabrielli E., Kenno S., Perito S., Cenci E., et al. Elucidating the immunological function of the Cryptococcus neoformans capsule. Future Microbiology 2013, 8:1107-1116.
226. Vecchiarelli A., Pietrella D., Dottorini M., Monari C., Retini C., Todisco T., et al. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clinical and Experimental Immunology 1994, 98:217-223.
227. Velagapudi R., Hsueh Y.P., Geunes-Boyer S., Wright J.R., Heitman J. Spores as infectious propagules of Cryptococcus neoformans. Infection and Immunity 2009, 77:4345-4355.
228. Villena S.N., Pinheiro R.O., Pinheiro C.S., Nunes M.P., Takiya C.M., DosReis G.A., et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cellular Microbiology 2008, 10:1274-1285.
229. Vu K., Eigenheer R.A., Phinney B.S., Gelli A. Cryptococcus neoformans promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells. Infection and Immunity 2013, 81:3139-3147.
230. Wang Y., Casadevall A. Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Applied and Environmental Microbiology 1994, 60:3864-3866.
231. Wang Y., Casadevall A. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrobial Agents and Chemotherapy 1994, 38:2648-2650.
232. Wang Y., Casadevall A. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infection and Immunity 1994, 62:3004-3007.
233. Waterman S.R., Park Y.-D., Raja M., Qiu J., Hammoud D.A., O'Halloran T.V., et al. Role of CTR4 in the Virulence of Cryptococcus neoformans. mBio 2012, 3:e00285-12.
234. Williamson P.R. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Frontiers in Bioscience: A Journal and Virtual Library 1997, 2:e99-e107.
235. Wolf J.M., Rivera J., Casadevall A. Serum albumin disrupts Cryptococcus neoformans and Bacillus anthracis extracellular vesicles. Cellular Microbiology 2012, 14:762-773.
236. Wozniak K.L., Levitz S.M. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infection and Immunity 2008, 76:4764-4771.
237. Yoneda A., Doering T.L. A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. Molecular Biology of the Cell 2006, 17:5131-5140.
238. Zaragoza O., Garcia-Rodas R., Nosanchuk J.D., Cuenca-Estrella M., Rodriguez-Tudela J.L., Casadevall A. Fungal cell gigantism during mammalian infection. PLoS Pathogens 2010, 6:e1000945.
239. Zaragoza O., Rodrigues M.L., De Jesus M., Frases S., Dadachova E., Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Advances in Applied Microbiology 2009, 68:133-216.